For decades, the pharmaceutical industry has relied heavily on animal models to test the safety and efficacy of emerging therapeutics. Yet, fundamental biological differences between species mean that a drug performing successfully in a mouse or a larger animal frequently fails when translated to human clinical trials. Most pharmaceutical candidates still ultimately fail during development, costing companies billions of dollars and years of research. <\/p>\n
To bridge this critical translational gap, a Denver-based startup called Intero Biosystems is pioneering the commercial production of human intestinal organoids\u2014sophisticated, lab-grown tissues that mimic the complex architecture of the human gut. By offering a more accurate representation of human biology, the company aims to supplement traditional animal testing and provide researchers with reliable physiological models long before compounds are ever administered to human volunteers.<\/p>\n
Spun out of the University of Michigan, Intero emphasizes that its organoids stand apart from simpler in-vitro models that only replicate a single layer of cells or isolated portions of the digestive tract. Co-founder and Chief Technology Officer Madeline Eiken noted that GastroScreen, the company’s flagship product, contains multiple distinct cell and tissue types found naturally in the human intestine, creating a far more human-relevant testing environment.<\/p>\n
"Most drugs fail clinical trials, and I think it\u2019s pretty easy to appreciate that we are neither mice nor flat layers of cells," Eiken remarked.<\/p>\n
Intero\u2019s flagship product, GastroScreen, is designed specifically for commercial sale to pharmaceutical, biotechnology, food, and chemical companies seeking advanced testing platforms. Each organoid measures approximately one millimeter across, and the company routinely packages and ships roughly 100 of these living miniature organs at a time inside a standard mailing tube. <\/p>\n
"We\u2019re literally shipping mini living organs in the mail to people," said co-founder and Chief Executive Officer Charlie Childs. <\/p>\n
Clients utilize these organoids in two primary states: as healthy intestinal models or as chemically induced disease-like conditions. This flexibility allows researchers to observe how living human tissue responds to novel drug candidates, environmental toxins, or food ingredients under both normal and pathological circumstances.<\/p>\n
Beyond the living tissue itself, Intero operates as an end-to-end provider for its growing customer base. The startup sells proprietary supplies required to sustain and experiment with the organoids, including specialized nutrient media formulations that feed the cells and specific chemical reagents used during testing protocols. Furthermore, Intero conducts contracted research studies directly for its clients. This service encompasses designing custom experiments, executing complex laboratory assays, and delivering comprehensive datasets. Much of this contracted work centers on assessing drug safety, such as exposing organoids to experimental molecules to detect potential gastrointestinal toxicity, or investigating underlying mechanisms of gut diseases.<\/p>\n
Founded in 2024, Intero has steadily expanded its footprint. The startup currently employs seven people and maintains a portfolio of just under 10 active customers. This commercial traction follows a $2.3 million pre-seed funding round secured last year. According to the CEO, the company generated more than $400,000 in revenue from the fourth quarter of last year through the third quarter of this year.<\/p>\n
Growing industry interest in human-relevant biological models is increasingly influenced by evolving regulatory frameworks. In April of last year, the U.S. Food and Drug Administration (FDA) unveiled strategic plans to reduce its reliance on mandatory animal testing requirements, specifically targeting monoclonal antibodies and other classes of drugs. The agency actively promoted alternative methodologies, including organoids, microfluidic organs-on-chips, and artificial intelligence-driven computational models.<\/p>\n
Building on that momentum, the FDA issued draft guidance outlining how drug developers should validate new approach methodologies\u2014collectively referred to as NAMs\u2014when submitting data to support regulatory approvals. While the guidance establishes a structured framework for validation, it stops short of endorsing any single proprietary technology. Instead, the regulatory viability of any given NAM depends heavily on the specific methodology, its intended application, and the robustness of the data provided.<\/p>\n
According to Eiken, statutory updates in U.S. law permitting drug developers to utilize non-animal testing approaches under specific circumstances have fundamentally altered industry attitudes. Pharmaceutical companies that were previously hesitant to adopt unproven technologies are now actively seeking to bring organoid systems directly into their internal research pipelines.<\/p>\n
Intero is not alone in its pursuit of advanced, human-relevant gastrointestinal models. The market includes several competitors deploying alternative tissue engineering strategies. Altis Biosystems develops specialized stem cell-derived intestinal models, while InSphero offers patient-derived intestinal organoids tailored primarily for gastrointestinal toxicity screening. Meanwhile, companies like MIMETAS take a microfluidic approach, utilizing organ-on-chip technology to recreate dynamic mechanical and fluid environments characteristic of human tissues.<\/p>\n
Intero argues that its competitive advantage lies in the unique complexity and scalability of GastroScreen. Unlike traditional intestinal models derived from primary tissue harvested via invasive procedures like colonoscopies, GastroScreen is generated from induced pluripotent stem cells. These are adult cells reprogrammed back into an embryonic-like state capable of differentiating into virtually any cell type in the body, and they can be conveniently sourced from a simple blood draw. Eiken explains that this methodology gives the startup a distinct pathway to personalize its models for individual patients while simultaneously scaling production far more efficiently than competitors relying on primary human tissue biopsies.<\/p>\n
When questioned about empirical evidence proving that GastroScreen predicts human clinical responses more accurately than conventional animal or monolayer cell models, Childs noted that the company is actively progressing through a structured, three-stage validation pipeline. Having already demonstrated that GastroScreen successfully harbors all critical cell types native to the human gut, Intero is currently executing the second phase: testing well-documented pharmacological agents with established clinical histories in humans. <\/p>\n
Childs reported that GastroScreen has already demonstrated expected physiological responses when exposed to anti-inflammatory drugs that mitigate intestinal distress, as well as toxic compounds known to inflict gut damage. In the third and final stage of validation, Intero intends to compare GastroScreen data directly against existing animal and clinical datasets provided by its pharmaceutical partners. These comparative studies are currently underway with several drug developers, evaluating both legacy compounds and unreleased drug candidates.<\/p>\n
Intriguingly, Intero does not utilize artificial intelligence to design or grow its organoids. Rather, Childs views the physical organoids as a vital biological engine capable of generating the high-fidelity empirical data that modern AI models desperately require. The company ultimately plans to license these proprietary biological datasets directly to pharmaceutical enterprises and artificial intelligence firms.<\/p>\n
In the near term, Intero\u2019s operational focus centers on industrializing its manufacturing processes. The startup can currently yield a few thousand organoids per production batch, but it is actively engineering automated systems to scale output into hundreds of thousands per run. <\/p>\n
Over the long term, the company aspires to venture into personalized medicine, leveraging individual patient cells to construct bespoke organoids capable of predicting personal therapeutic responses before a patient undergoes treatment. The startup’s most ambitious ultimate vision is the creation of a fully functional artificial intestine, an objective that Childs believes will naturally emerge from the convergence of large-scale organoid manufacturing and patient-specific biological insights.<\/p>\n
Intero presented its technology at TechCrunch Disrupt, where the startup is competing alongside 19 other early-stage companies for this year\u2019s Startup Battlefield crown in downtown San Francisco.<\/p>\n","protected":false},"excerpt":{"rendered":"
For decades, the pharmaceutical industry has relied heavily on animal models to test the safety and efficacy of emerging therapeutics. Yet, fundamental biological differences between species mean that a drug performing successfully in a mouse or a larger animal frequently fails when translated to human clinical trials. Most pharmaceutical candidates still ultimately fail during development, […]<\/p>\n","protected":false},"author":1,"featured_media":750,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[607],"tags":[878,884,876,885,610,886,244,880,433,881,877,882,879,112,609,883,608],"class_list":["post-751","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-venture-capital-startups","tag-biosystems","tag-cost","tag-denver","tag-drug","tag-entrepreneurship","tag-failure","tag-funding","tag-grown","tag-high","tag-human","tag-intero","tag-intestines","tag-ships","tag-startup","tag-startups","tag-tackle","tag-venture-capital"],"_links":{"self":[{"href":"https:\/\/financepoetry.com\/index.php?rest_route=\/wp\/v2\/posts\/751","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/financepoetry.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/financepoetry.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/financepoetry.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/financepoetry.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=751"}],"version-history":[{"count":0,"href":"https:\/\/financepoetry.com\/index.php?rest_route=\/wp\/v2\/posts\/751\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/financepoetry.com\/index.php?rest_route=\/wp\/v2\/media\/750"}],"wp:attachment":[{"href":"https:\/\/financepoetry.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=751"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/financepoetry.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=751"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/financepoetry.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=751"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}